Cetuximab is Associated With Excessive Toxicity When Combined With Bevacizumab Plus mFOLFOX6 in Metastatic Colorectal Carcinoma

BACKGROUND: The bevacizumab-cetuximab combination has shown promising activity in chemotherapy-refractory metastatic colorectal cancer (mCRC). We sought to determine the safety and efficacy of cetuximab added to bevaci-zumab plus standard mFOLFOX6 (modified 5-fluorouracil [5-FU]/leucovorin/oxaliplat...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ocean, Allyson J., Polite, Blase, Christos, Paul, Horvath, Lisa, Hamilton, Anne, Matulich, Daniel, Chen, Helen X., Sparano, Joseph A., Kindler, Hedy L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3623373/
https://ncbi.nlm.nih.gov/pubmed/21208843
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CCC.2010.n.042
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi